EUVIMEDEUVIMED entdecken
Crossref

CAR-ving away OX40L with engineered T regs

Jonathan S Maltzman iD

Science Immunology · 2024

DOI: 10.1126/sciimmunol.adu0983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Jonathan S Maltzman. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, OX40 Ligand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OX40L–CAR-T regs show promise for treating autoimmunity and transplantation rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryOX40 LigandHumansAnimalsGraft RejectionReceptors, Chimeric AntigenImmunotherapy, Adoptive

Substanzen

OX40 LigandReceptors, Chimeric AntigenTNFSF4 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Geriatric Research and Education and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA, USA.

ORCID-Profile: Jonathan S Maltzman

Zitieren

APA

Maltzman, J. S. (2024). CAR-ving away OX40L with engineered T regs. Science Immunology. https://doi.org/10.1126/sciimmunol.adu0983

Vancouver

Maltzman JS. CAR-ving away OX40L with engineered T regs. Science Immunology. 2024. doi:10.1126/sciimmunol.adu0983

BibTeX
@article{Maltzman2024,
  author = {Maltzman, Jonathan S},
  title = {CAR-ving away OX40L with engineered T regs},
  journal = {Science Immunology},
  year = {2024},
  doi = {10.1126/sciimmunol.adu0983}
}
Kostenlos starten →